Response of choline metabolites to docetaxel therapy is quantified in vivo by localized 31P MRS of human breast cancer xenografts and in vitro by high-resolution 31P NMR spectroscopy of cell extracts

Magnetic Resonance in Medicine

Volumn 58, Issue 2, 2007, Pages 270-280

  Morse, David L ^a   Raghunand, Natarajan ^a   Sadarangani, Pooja ^a   Murthi, Shiva ^a   Job, Constantin ^b   Day, Sam ^a   Howison, Christine ^b   Gillies, Robert J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Breast cancer; Glycerophosphocholine; MRS; Phosphocholine; Phosphorous

Indexed keywords

CELL CULTURE; DISASTERS; DISEASES; METABOLITES; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RESONANCE; TUMORS;

31P-NMR SPECTROSCOPY; ANTI-MICROTUBULE DRUGS; BREAST CANCER; GLYCEROPHOSPHOCHOLINE; HIGH RESOLUTION NMR SPECTROSCOPY; HUMAN BREAST CANCER CELLS; PHOSPHOCHOLINE; PHOSPHOROUS;

CELL DEATH;

BIOLOGICAL MARKER; CHOLINE; DOCETAXEL; PHOSPHORYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL STRAIN MCF 7; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; METABOLITE; MITOSIS; MOUSE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 34547961543     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21333     Document Type: Article

References (57)

1. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992;5:303-324.
2. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999;12:413-439.
3. 31P measurements of response to treatment. NMR Biomed 1998;11:314-340.
4. Ronen SM, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res 2001;3:36-40.
5. Morse DL, Gillies RJ. Choline containing compounds as diagnostic, prognostic and therapeutic response indicators for breast cancer. In: NR Jagannathan, editor. Recent advances in MR imaging and spectroscopy, New Delhi: Jaypee Brothers Medical Publishers, Ltd.; 2005. p 345-397.
6. Gillies RJ, Morse DL. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng 2005;7:7.1-7.40.
7. Jagannathan NR, Singh M, Govindaraju V, Raghunathan P, Coshic O, Julka PK, Rath GK. Volume localized in vivo proton MR spectroscopy of breast carcinoma: variation of water-fat ratio in patients receiving chemotherapy. NMR Biomed 1998;11:414-422.
8. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998;209:269-275.
9. Gribbestad IS, Singstad TE, Nilsen G, Fjosne HE, Engan T, Haugen OA, Rinck PA. In vivo H-1 MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging 1998;8:1191-1197.
10. Kvistad KA, Bakken IJ, Gribbestad IS, Ehrnholm B, Lundgren S, Fjosne HE, Haraldseth O. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 1999;10:159-164.
11. 1H MR spectroscopy. Magn Reson Med 2003;50:1134-1143.
12. Seenu V, Kumar MNP, Sharma U, Gupta D, Mehta SN, Jagannathan NR. Potential of magnetic resonance spectroscopy to detect metastasis in axillary lymph nodes in breast cancer. Magn Reson Imaging 2005;23:1005-1010.
13. 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: Preliminary results of observer performance study at 4.0 T. Radiology 2005;236:465-475.
14. 1H MR spectroscopy using water as an internal reference at 1.5 T. MAGMA 2006;19:96-104.
15. Bartella L, Morris EA, Dershaw D, Liberman L, Thakur SB, Moskowitz C, Guido J, Huang W. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology 2006;239:686-692.
16. 1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue. NMR Biomed 1994;7:181-194.
17. Oberhaensli RD, Bore PJ, Rampling RP, Hiltonjones D, Hands LJ, Radda GK. Biochemical investigation of human-tumors in vivo with P-31 magnetic-resonance spectroscopy. Lancet 1986;2:8-11.
18. 31P MRS study. Br J Cancer 1993;67:1145-1153.
19. Twelves CJ, Porter DA, Lowry M, Dobbs NA, Graves PE, Smith MA, Rubens RD, Richards MA. Phosphorus-31 metabolism of post-menopausal breast cancer studied in vivo by magnetic resonance spectroscopy. Br J Cancer 1994;69:1151-1156.
20. Merchant TE, Gierke LW, Meneses P, Glonek T. P 31 Magnetic-resonance spectroscopic profiles of neoplastic human-breast tissues. Cancer Res 1988;48:5112-5118.
21. 31P NMR spectra from human breast tumours: variations in phospholipid metabolism. Br J Cancer 1991;63:514-516.
22. Barzilai A, Horowitz A, Geier A, Degani H. Phosphate metabolites and steroid hormone receptors of benign and malignant breast tumors. A nuclear magnetic resonance study. Cancer 1991;67:2919-2925.
23. Sijens PE, Wijrdeman HK, Moerland MA, Bakker CJ, Vermeulen JW, Luyten PR. Human-breast cancer in vivo - H-1 and P-31 MR spectroscopy at 1.5-T. Radiology 1988;169:615-620.
24. Ng TC, Grundfest S, Vijayakumar S, Baldwin NJ, Majors AW, Karalis I, Meaney TF, Shin KH, Thomas FJ, Tubbs R. Therapeutic response of breast-carcinoma monitored by P-31 MRS in situ. Magn Reson Med 1989;10:125-134.
25. Glaholm J, Leach MO, Collins DJ, Mansi J, Sharp JC, Madden A, Smith IE, McCready VR. In vivo P-31 magnetic-resonance spectroscopy for monitoring treatment response in breast-cancer. Lancet 1989;1:1326-1327.
26. Redmond OM, Stack JP, Oconnor NG, Carney DN, Dervan PA, Hurson BJ, Ennis JT. P-31 MRS as an early prognostic indicator of patient response to chemotherapy. Magn Reson Med 1992;25:30-44.
27. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001;84:1016-1022.
28. 1H MR spectroscopy - a pilot study at 4 T. Radiology 2004;233:424-431.
29. Jordan BF, Black K, Robey IF, Runquist M, Powis G, Gillies RJ. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed 2005;18:430-439.
30. Evelhoch JL, Keller NA, Corbett TH. Response-specific adriamycin sensitivity markers provided by in vivo 31P nuclear magnetic resonance spectroscopy in murine mammary adenocarcinomas. Cancer Res 1987;47:3396-3401.
31. Koutcher JA, Alfieri AA, Devitt ML, Rhee JG, Kornblith AB, Mahmood U, Merchant TE, Cowburn D. Quantitative changes in tumor metabolism, partial pressure of oxygen, and radiobiological oxygenation status postradiation. Cancer Res 1992;52:4620-4627.
32. Gillies RJ, Galons JP, McGovern KA, Scherer PG, Lien YH, Job C, Ratcliff R, Chapa F, Cerdan S, Dale BE. Design and application of NMR-compatible bioreactor circuits for extended perfusion of high-density mammalian-cell cultures. NMR Biomed 1993;6:95-104.
33. 13C-NMR studies. Biochim Biophys Acta 1990;1052:255-263.
34. 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin. Magn Reson Med 2002;48:819-825.
35. Natarajan K, Mori N, Artemov D, Bhujwalla ZM. Exposure of human breast cancer cells to the anti-inflammatory agent indomethacin alters choline phospholipid metabolites and Nm23 expression. Neoplasia 2002;4:409-416.
36. 31P-magnetic resonance spectroscopy study. Cancer Res 2001;61:7536-7543.
37. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991;83:288-291.
38. Crown J, O'Leary M. The taxanes: an update. Lancet 2000;355:1176-1178.
39. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747-2755.
40. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, Andre S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995;22:3-16.
41. Mahmood U, Alfieri AA, Thaler H, Cowburn D, Koutcher JA. Radiation dose-dependent changes in tumor metabolism measured by 31P nuclear magnetic resonance spectroscopy. Cancer Res 1994;54:4885-4891.
42. Street JC, Alfieri AA, Traganos F, Koutcher JA. In vivo and ex vivo study of metabolic and cellular effects of 5-fluorouracil chemotherapy in a mouse mammary carcinoma. Magn Reson Imaging 1997;15:587-596.
43. 31P MRS in in vivo human brain. Magn Reson Med 1999;42:643-654.
44. Jensen JE, Drost DJ, Menon RS, Williamson PC. In vivo brain P-31-MRS: measuring the phospholipid resonances at 4 Tesla from small voxels. NMR Biomed 2002;15:338-347.
45. Bogin L, Papa MZ, Polak-Charcon S, Degani H. TNF-induced modulations of phospholipid metabolism in human breast cancer cells. Biochim Biophys Acta 1998;1392:217-232.
46. Morse DL, Gray H, Payne CM, Gillies RJ. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 2005;4:1495-1504.
47. Morse DL, Galons JP, Payne CM, Jennings D, Day S, Xia G, Gillies RJ. MRI-measured water mobility increases in response to docetaxel-induced cell death via multiple mechanisms. NMR Biomed 2007 (Epub ahead of print).
48. Jennings D, Hatton BN, Guo JY, Galons JP, Trouard TP, Raghunand N, Marshall J, Gillies RJ. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 2002;4:255-262.
49. Paine-Murrieta GD, Taylor CW, Curtis RA, Lopez MH, Dorr RT, Johnson CS, Funk CY, Thompson F, Hersh EM. Human tumor models in the severe combined immune deficient (SCID) mouse. Cancer Chemother Pharmacol 1997;40:209-214.
50. Taetle R, Jones OW, Honeysett JM, Abramson I, Bradshaw C, Reid S. Use of nude mouse xenografts as preclinical screens. Characterization of xenograft-derived melanoma cell lines. Cancer 1987;60:1836-1841.
51. Connelly A, Counsell C, Lohman JAB, Ordidge RJ. Outer volume suppressed image related in vivo spectroscopy (OSIRIS), a high-sensitivity localization technique. J Magn Reson 1988;78:519-525.
52. Katz-Brull R, Margalit R, Degani H. Differential routing of choline in implanted breast cancer and normal organs. Magn Reson Med 2001;46:31-38.
53. Bradford MM. Rapid and sensitive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Anal Biochem 1976;72:248-254.
54. Tyagi RK, Azrad A, Degani H, Salomon Y. Simultaneous extraction of cellular lipids and water-soluble metabolites: Evaluation by NMR spectroscopy. Magn Reson Med 1996;35:194-200.
55. Theilmann RJ, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Moore J, Gillies RJ. Changes in water mobility by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 2004;6:831-837.
56. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? - treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001;4:303-313.
57. 31P NMR spectroscopy. NMR Biomed 1995;8:149-158.